Results 81 to 90 of about 56,519 (290)

Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country

Brazilian Journal of Psychiatry
Objective: The aim of our study was to examine the prevalence of and factors associated with antipsychotic polypharmacy (APP) among patients with serious mental illness in the current South African health care context.
Kerryn S. Armstrong, Henk Temmingh
doaj   +1 more source

Psychosocial and Biological Factors Contributing to Body Weight Gain in Schizophrenia [PDF]

, 2011
Overweight and obesity are frequently reported to be a significant issue in schizophrenia resulting in the inherent complications of these disorders.
Pai, NB, Vella, SC
core   +2 more sources

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Sex Differences in Aripiprazole Sensitization from Adolescence to Adulthood [PDF]

, 2018
The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or
Chow, Shinnyi, Davis, Collin, Freeman, Elizabeth, Li, Ming, Lin, Joanne   +4 more
core   +1 more source

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota, David J. Grelotti, Tyler Nguyen, Walter H. Kaye, Skylar Swindle, Raymond Suhandynata, Spencer Seely, Megan E. Shott, Guido K. W. Frank   +8 more
wiley   +1 more source

Antipsychotic Drug Poisoning in Children Under 12 Years Old in Loghman-Hakim Hospital During 2016-2022

International Journal of Medical Toxicology and Forensic Medicine
Background: Unintentional pediatric poisoning with antipsychotic medications represents an important clinical entity. This study aimed to evaluate the epidemiology, clinical manifestations, and outcomes of antipsychotic poisoning among children ...
Fariba Farnaghi, Pooya Eini, Latif Gachkar   +2 more
doaj   +1 more source

Cannabis and schizophrenia [PDF]

, 2014
BACKGROUND Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations. Many people with schizophrenia smoke cannabis, and it is unclear why a large proportion do so and if the effects are harmful or beneficial. It is also unclear
Gillies, Donna, Kalakouti, Eliana, Kyprianou, Katerina, McLoughlin, Benjamin C., Pushpa-Rajah, Jonathan A., Rathbone, John, Variend, Hannele   +6 more
core   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

Neuropsychiatric Disease and Treatment, 2009
Xinhua S Ren1,2,3, Lawrence Herz4,5, Shirley Qian1,2,3, Eric Smith3,4, Lewis E Kazis1,2,31The Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School of Public Health, Boston, MA, USA; 2Department of ...
Xinhua S Ren, Lawrence Herz, Shirley Qian, et al   +3 more
doaj  

Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules

Neurobiology of Disease, 2013
Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for ...
Akihiro Mouri, Taku Nagai, Daisuke Ibi, Kiyofumi Yamada   +3 more
doaj   +1 more source